In8Bio (INAB) Shares Outstanding (2020 - 2026)
In8Bio (INAB) posted Shares Outstanding (Entity) of $19.5 million for Q1 2026, up 345.03% sequentially from $4.4 million in Q4 2025, and up 618.78% YoY from $2.7 million in Q1 2025.
In8Bio (INAB) Shares Outstanding (2020 - 2026) Analysis & Trends
In8Bio has reported Shares Outstanding (Entity) for 7 years, with the latest figure at $19.5 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 618.78% year-over-year to $19.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.5 million (up 618.78% YoY) and the FY2025 annual result came in at $4.4 million, up 145.1% from the prior year.
- Shares Outstanding (Entity) climbed to $19.5 million in Q1 2026 per INAB's latest filing, from $4.4 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $19.5 million in Q1 2026 and troughed at $627013.0 in Q1 2022.
- A 5-year average of $2.8 million and a median of $1.4 million in 2024 frame the typical range for Shares Outstanding (Entity).
- The sharpest annual moves came in 2023 and 2026: Shares Outstanding (Entity) rose 21.67% in 2023, then soared 618.78% in 2026.
- Over 5 years, Shares Outstanding (Entity) stood at $818090.0 in 2022, then gained by 21.67% to $995398.0 in 2023, then surged by 79.3% to $1.8 million in 2024, then soared by 145.1% to $4.4 million in 2025, then soared by 345.03% to $19.5 million in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $19.5 million, $4.4 million, and $4.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | In8Bio | 24.34 Mn | 24.34 Mn | - | 19.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.47 Mn |
| Mar 31, 2026 | 19.47 Mn |
| Dec 31, 2025 | 4.37 Mn |
| Sep 30, 2025 | 4.54 Mn |
| Jun 30, 2025 | 4.12 Mn |
| Mar 31, 2025 | 2.78 Mn |
| Dec 31, 2024 | 1.78 Mn |
| Sep 30, 2024 | 1.58 Mn |
| Jun 30, 2024 | 1.50 Mn |
| Mar 31, 2024 | 1.44 Mn |
| Dec 31, 2023 | 995,398.00 |
| Sep 30, 2023 | 1.05 Mn |
| Jun 30, 2023 | 948,983.00 |
| Mar 31, 2023 | 824,337.00 |
| Dec 31, 2022 | 698,862.00 |
| Sep 30, 2022 | 721,979.00 |
| Jun 30, 2022 | 627,560.00 |
| Mar 31, 2022 | 626,622.00 |
| Dec 31, 2021 | 332,291.00 |
| Sep 30, 2021 | 445,878.00 |